Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
Status:
Completed
Trial end date:
2020-12-14
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in
comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (HeFH, or
non-HeFH with a history of clinical ASCVD) with persistent hypercholesterolemia despite
receiving maximally-tolerated LMT. Persistent hypercholesterolemia is defined as LDL-C ≥70
mg/dL (1.81 mmol/L) for those patients with clinical ASCVD and LDL-C ≥100 mg/dL (2.59 mmol/L)
for those patients without clinical ASCVD.